NasdaqCM:CORTPharmaceuticals
Assessing Corcept Therapeutics (CORT) Valuation After FDA Relacorilant Setback And Legal Investigations
Corcept Therapeutics (CORT) is back in focus after the FDA issued a Complete Response Letter for relacorilant, requesting more evidence of effectiveness, while several law firms launched investigations tied to the drug’s regulatory disclosures.
See our latest analysis for Corcept Therapeutics.
Those regulatory setbacks and legal probes help explain why Corcept’s 90 day share price return is a 42.74% decline, while its 1 year total shareholder return is a 38.83% loss. At the same time, the 3...